Please assess the completion status of the following clinical trial:

Trial Title: SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Skeletally mature patients age 25 - 70 years, inclusive~* Chronic lower back pain for at least six (6) months~* Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirement is as follows:~  * Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy~ * Supervised exercise program(minimum of 12 sessions)~* Oswestry Disability Index (ODI) at time of evaluation of at least 30 points~* Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale~* The following test indicating that the vertebral body is the source of pain:~  1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1~* Understands the local language and is willing and able to follow the requirements of the protocol~* Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form~Exclusion Criteria:~* Radicular pain by history or evidence of pain or neurological deficit in a dermatomal zone at or below the medial thigh.~* Previous surgery performed on the lumbar spine~* History of symptomatic spinal stenosis~* History of osteoporotic or tumor-related vertebral body compression fracture~* History of vertebral cancer or spinal metastasis~* History of spinal infection~* Metabolic bone disease (e.g. osteogenesis imperfecta)~* BMI ≥40~* Osteoporosis, defined as T score \<-2.5~* Any radiographic evidence of other important back pathology, such as:~  1. Nerve root compression or severe effacement of the thecal sac that correlates with radicular pain or muscle weakness~ 2. Disc extrusion or disc protrusion \>5mm~ 3. Facet arthrosis or facet effusion at any lumbar level that correlates with clinical evidence of facet mediated low back pain~ 4. Spondylolisthesis 2mm or greater at any level~ 5. Spondylolysis at any level~* MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.~* Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain~* Demonstrates 3 or more Waddell's signs of Inorganic Behavior~* Any evidence of current systemic infection~* Uncorrected bleeding diathesis~* Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI~* Contraindication to MRI or patients who have allergies to the components of the Intracept device~* Pregnant, lactating or plan to become pregnant in next year~* Diabetes requiring daily insulin~* Current use of steroid therapy, with the exception of inhalation steroids for asthma~* Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible~* Receiving Workmen's Compensation~* Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired~* Any medical condition that impairs follow-up~* Contraindications to the proposed anesthetic protocol.~* Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin)~* Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months~* Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)~* Has a life expectancy of less than 1 year~* Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc.~* Is a prisoner

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intracept Treatment (Type: EXPERIMENTAL): None
- Sham Treatment (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete